Drug Trial Radar · NCT04333108
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
Last checked: Nov 20, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Jul 1, 2020
Primary completion
Dec 2024
Study completion Jun 2025
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell mediator release, unresponsive to optimal symptomatic treatment.
Conditions
- Indolent Systemic Mastocytosis
Interventions
MasitinibDrug
Masitinib 6 mg/kg/day
PlaceboOther
Matching placebo
Best Supportive CareOther
Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative response (3R75%)Time frame: 24 weeks
Locations
17 sites in 8 countries. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire d'Amiens
Amiens, France · Recruiting
Hospital Jean-Minjoz
Besançon, France · Recruiting
Grenoble University Hospital
Grenoble, France · Recruiting
Hospital Claude Huriez
Lille, France · Recruiting
Marseille University Hospital Timone
Marseille, France · Recruiting
Centre de référence de Mastocytose (CEREMAST)
Paris, France · Recruiting
Poitiers University Hospital
Poitiers, France · Recruiting
Centre Hospitalier Universitaire
Toulouse, France · Recruiting
University Hospital Charité
Berlin, Germany · Not yet recruiting
Erasmus University Medical Center
Rotterdam, Netherlands · Recruiting
Medical University of Gdańsk
Gdansk, Poland · Recruiting
The University Hospital in Krakow (Szpital Uniwersytecki w Krakowie)
Krakow, Poland · Recruiting
University Hospital in Bucharest (Spitalul Universitar de Urgență București)
Bucharest, Romania · Recruiting
Almazov National Medical Research Centre
Saint Petersburg, Russia · Recruiting
Dnipropetrovsk Clinical Association of Emergency Medical Care of Dnipropetrovsk Regional
Dnipro, Ukraine · Recruiting
Private Enterprise Private Manufacturing Company Acinus
Poltava, Ukraine · Recruiting
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.